Cook Biotech acquires assets from Parsolex GMP Center Inc., expanding its drug delivery capabilities

West Lafayette, Indiana—Cook Biotech Incorporated, a leader in advanced biomaterials and regenerative medicine, acquires employees and equipment from Parsolex, an advanced contract development and manufacturing organization (CDMO) with state-of-the-art drug manufacturing capabilities. In addition, Cook Biotech purchased the building from the Purdue Research Foundation.

Established in 2004, Parsolex is a CDMO with capabilities in analytical testing, formulation development, and strategic advisory. Since 2016, Parsolex has invested heavily in acquiring and building human talent, developing proprietary systems, and expanding operational infrastructure to solidify its position as a world-class oral solid dosage form CDMO. Its clients have included hospitals, academic institutions, start-ups, and multinational pharmaceutical companies.

Acquiring the team members, building improvements, and building, which is across the street from the main Cook Biotech building in the Purdue Research Park in West Lafayette, IN, is a natural next step in Cook Biotech’s strategy for developing a drug delivery business synergistic with its biomaterial platforms. Some of Cook Biotech’s most promising projects involve using these biomaterials with drug products to provide solutions for critical unmet medical needs. This purchase adds drug product manufacturing and GMP analytical testing to Cook Biotech’s current medical device manufacturing capabilities.

In 2021, Cook Biotech purchased the assets of AcuityBio to accelerate bringing a lung cancer treatment to market. The next step in bringing this and other drug delivery technologies to market was purchasing assets from Parsolex.

Cook Biotech president Umesh Patel said, “This is an exciting next step in our ability to deliver drugs with our biomaterial platforms, improving patient outcomes for lung cancer and other medical needs. We are acquiring all the pieces we need to take our drug delivery projects to the next level and serve more patients around the world. We are in a unique position to take these assets and combine them with our own resources to become a global leader in new drug delivery technologies.”

The acquisition of these assets opens new horizons in drug delivery for Cook Biotech, its partners, and the Cook Group, and it accelerates the ability to get drug delivery products to the market.

The terms of the agreement remain confidential.

About Cook Biotech Incorporated:

For more than 25 years, Cook Biotech Incorporated, a leader in regenerative medicine, has partnered with surgeons, existing companies, academic institutions, and startup companies. Our expertise spans extracellular matrices, drug delivery, process development, manufacturing, regulatory, and quality. We are committed to innovating to address unmet clinical needs. We have recently invested in novel drug delivery platforms and biosynthetic materials. Cook Biotech labeled products are available globally under several brand names including Biodesign^® and OASIS^®. Cook Biotech is headquartered in West Lafayette, Indiana, USA, and is a member of the Cook Group of companies. Learn more about Cook Biotech at cookbiotech.com.